Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.73 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.58 |
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.56 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430650 | 0.88 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL30410369 | 0.87 | EPHX2 (0.68) | EPHX2KDM4EALDH1A1 | |
| SCHEMBL1431503 | 0.85 | NAMPT (0.58) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL3945175 | 0.84 | EPHX2 (1.00) | EPHX2L3MBTL3L3MBTL1PIK3CAMTOR | |
| SCHEMBL12237815 | 0.80 | L3MBTL3 (0.79) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL94754 | 0.80 | L3MBTL3 (0.79) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL10293564 | 0.80 | L3MBTL3 (0.78) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL32568 | 0.78 | PIK3CA (0.93) | EPHX2PIK3CAMTORPIK3CG | |
| SCHEMBL17886717 | 0.77 | L3MBTL3 (0.73) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL21360592 | 0.77 | L3MBTL3 (0.68) | EPHX2L3MBTL3L3MBTL1MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| US-9174963-B2 | Triazine compounds as PI3 kinase and MTOR inhibitors | PFIZER INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2015-01-08 | — | — | US | disclosed |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8748421-B2 | Triazine compounds as P13 kinase and MTOR inhibitors | WYETH LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8575159-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8445486-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | EPHX2 4453/4885L3MBTL3 1605/4885L3MBTL1 2650/4885 |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | EPHX2 4453/4885L3MBTL3 1605/4885L3MBTL1 2650/4885 |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | EPHX2 4461/4885L3MBTL3 1963/4885L3MBTL1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.